Dr. Carothers studies several important areas in medical research and technology. He has explored effective treatments for conditions like migraines, schizoaffective disorder, and the recovery from strokes. For instance, he developed a new delivery method for migraine medication that showed significantly improved relief rates. In the realm of gene therapy, he has investigated how the design of genetic tools, like CRISPR, can be optimized for better precision. Furthermore, his research on engineered living materials offers insights into how microbes can be used more effectively for producing beneficial compounds sustainably. This diverse focus helps advance medical treatments and scientific methodologies that can benefit various patient populations.
Key findings
In a study on migraine treatment, 68% of patients experienced relief within two hours using AVP-825, compared to 45% using a placebo.
Patients treated with a higher dose of paliperidone showed a significant symptom improvement in schizoaffective disorder, with an average decrease of 32.4 points on PANSS scores, compared to 24.1 points for those on placebo.
In hip replacement surgery, 85% of patients using a new modular design achieved proper leg length and hip position, compared to only 60% using the traditional design.
The use of engineered living materials resulted in improved production rates of beneficial compounds through 3D spatial control of microbes.
Shorter or slightly mismatched RNA segments in CRISPR technology can create stronger binding connections, improving gene editing precision.
Frequently asked questions
Does Dr. Carothers study migraine treatments?
Yes, he has developed and researched innovative delivery methods for migraine medications that improve patient outcomes.
What conditions has Dr. Carothers researched treatments for?
He has worked on treatments for migraines, schizoaffective disorder, and recovery following strokes.
Is Dr. Carothers' work relevant to patients with genetic conditions?
Absolutely, his research on CRISPR technology focuses on improving gene editing techniques that can benefit patients needing gene therapy.
What advances has Dr. Carothers made in systems biology?
He has promoted best practices and standards that enhance collaboration and reproducibility in systems biology research.
How does Dr. Carothers' work relate to synthetic biology?
He studies self-driving labs that automate experiments, potentially transforming how researchers study biology aiming for better insights and innovations.
Publications in plain English
Bioproduction, bioprotection, and biocontainment in multi-Kingdom microbial systems with 3D spatial control.
2026
Biofabrication
Le L, Altin-Yavuzarslan G, Klatt EC, Sadaba N, Berg AC +7 more
Plain English This study looked at a new type of hybrid material called engineered living materials (ELMs) that combine microbes with a protective gel-like structure. The researchers found that by using 3D printing to arrange different microbes in specific patterns, they could improve how these materials produce beneficial compounds and protect themselves from harmful conditions. For example, they created structures that optimized the growth and function of two types of microbes, which can produce useful substances continuously.
Who this helps: This benefits scientists and industries working on sustainable bioproducts and bioreactors.
Perspectives for self-driving labs in synthetic biology.
2023
Current opinion in biotechnology
Martin HG, Radivojevic T, Zucker J, Bouchard K, Sustarich J +17 more
Plain English This research paper explores the idea of self-driving labs (SDLs), which use automation and artificial intelligence to conduct scientific experiments without human intervention. The authors believe that SDLs could transform how we study biology by focusing on DNA, the blueprint for all living things, to better understand how cells behave. They emphasize that investment in these labs is only worthwhile if it addresses significant biological questions.
Who this helps: This helps researchers and scientists working in synthetic biology.
Standards, dissemination, and best practices in systems biology.
2023
Current opinion in biotechnology
Shin J, Porubsky V, Carothers J, Sauro HM
Plain English This study focused on how to improve the reliability of models in systems biology research. The researchers found that following certain best practices, like using clear documentation and open-source code sharing, greatly increases the chances that other scientists can reproduce and build on existing models. Specifically, using established standards and well-organized repositories makes a significant difference in successful replication of experiments, enhancing collaboration in the field.
Who this helps: This helps researchers and scientists working in systems biology.
Complex dependence of CRISPR-Cas9 binding strength on guide RNA spacer lengths.
2021
Physical biology
Khakimzhan A, Garenne D, Tickman B, Fontana J, Carothers J +1 more
Plain English This study looked at how the length of RNA segments used in CRISPR technology affects the ability of this tool to accurately find and bind to specific genetic targets. Researchers found that shorter or slightly mismatched RNA segments can sometimes create stronger connections than the traditionally recommended lengths of 17-20 base pairs. This is important because it could improve the effectiveness of CRISPR for gene editing, making it more precise and versatile in various applications.
Who this helps: Patients needing gene therapy or doctors working in genetic research.
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
2015
Headache
Cady RK, McAllister PJ, Spierings EL, Messina J, Carothers J +2 more
Plain English This study looked at a new way to deliver a migraine medication called AVP-825, which uses a special device to spray a powder form of sumatriptan into the nose. The results showed that 68% of participants using AVP-825 experienced relief from their migraine pain within two hours, compared to 45% using a dummy treatment. This is important because fast relief can significantly improve a person's ability to function after a migraine.
Who this helps: This helps patients who suffer from migraines, especially those looking for quick relief from their pain.
Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
2013
Headache
Obaidi M, Offman E, Messina J, Carothers J, Djupesland PG +1 more
Plain English This study looked at how well a new Breath Powered device delivers sumatriptan powder for treating migraines compared to other forms of the medication, like a nasal spray, an oral tablet, and an injection. Researchers found that the Breath Powered device gave a higher peak level of the medication in the blood—20.8 ng/mL compared to 16.4 ng/mL from the nasal spray—despite delivering a lower total dose. This matters because it means patients may get quicker and more effective relief from their migraine symptoms with less medicine.
Who this helps: Patients suffering from migraines.
A comparison of two implant systems in restoration of hip geometry in arthroplasty.
2011
Clinical orthopaedics and related research
Archibeck MJ, Cummins T, Carothers J, Junick DW, White RE
Plain English This study compared two types of hip implants to see which one better restored the correct position and length of the leg following surgery. Researchers found that 85% of patients using a new design with two modular junctions achieved the desired leg length and hip position, compared to only 60% for those using a traditional design with one modular junction. This is important because getting the leg length and hip position right can lead to better outcomes for patients recovering from hip surgery.
Who this helps: Patients undergoing hip replacement surgery.
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
2010
The Journal of clinical psychiatry
Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J +2 more
Plain English This study tested the effectiveness and safety of two doses of paliperidone extended-release in treating schizoaffective disorder, a mental health condition that includes symptoms of both schizophrenia and mood disorders. Over six weeks, 316 participants were given either a higher dose (12 mg) or a lower dose (6 mg) of paliperidone, or a placebo. The results showed that those taking the higher dose had a significant improvement in their symptoms, with scores decreasing by an average of 32.4 points compared to 24.1 points for those on placebo.
Who this helps: This research benefits patients with schizoaffective disorder by providing effective treatment options.
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
2010
Journal of clinical psychopharmacology
Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C +3 more
Plain English This study looked at the effectiveness of paliperidone extended-release in treating patients with schizoaffective disorder over six weeks. Researchers found that patients taking paliperidone had a significant improvement in their symptoms compared to those on a placebo, with an average decrease in their PANSS scores of 20 points versus 10 points for the placebo group. This is important because it shows that paliperidone can help reduce both psychotic and mood symptoms in these patients, whether they are taking other mood stabilizers or antidepressants or not.
Who this helps: This benefits patients with schizoaffective disorder.
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
2009
The American journal of psychiatry
Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA +4 more
Plain English This study looked at the effectiveness of two medications, paliperidone extended-release and quetiapine, in treating hospitalized patients who had a recent worsening of schizophrenia. Over six weeks, patients taking paliperidone showed more significant improvement in their symptoms compared to those on quetiapine: by the end of the study, paliperidone patients had a change score of -23.4, while quetiapine patients had -17.1. This matters because it indicates that paliperidone may help patients feel better faster and more effectively than quetiapine, which is crucial for those experiencing severe episodes of schizophrenia.
Who this helps: This helps patients with schizophrenia and their doctors in choosing effective treatment options.
Polyethylene exchange in a second-generation cementless acetabular component.
2009
The Journal of arthroplasty
Archibeck MJ, Junick DW, Cummins T, Carothers J, White RE
Plain English This study looked at how safely and effectively doctors can replace a part called polyethylene in a specific type of hip implant without using cement. Researchers followed 29 patients who had this procedure over an average of 5 years. They found that only one patient experienced a problem with the new piece, which means that, overall, the procedure is safe and doesn't usually lead to complications.
Who this helps: This helps patients with hip implants who need a polyethylene replacement.
Hematopoietic origin of microglial and perivascular cells in brain.
2004
Experimental neurology
Hess DC, Abe T, Hill WD, Studdard AM, Carothers J +4 more
Plain English This research studied how specific blood cells from bone marrow can develop into different types of cells in the brain, particularly focusing on microglial and perivascular cells. The researchers found that these bone marrow-derived cells, marked with a green fluorescent protein, successfully transformed into brain-supporting cells after being transplanted into special mice, and their numbers increased after brain injuries. This is important because it shows a potential source of support cells in the brain that could respond to injury.
Who this helps: This benefits patients with brain injuries or diseases by providing insights into new treatment options.
Bone marrow as a source of endothelial cells and NeuN-expressing cells After stroke.
2002
Stroke
Hess DC, Hill WD, Martin-Studdard A, Carroll J, Brailer J +1 more
Plain English This study looked at how bone marrow cells can help repair the brain after a stroke. Researchers found that these cells could become part of the blood vessels and even develop into neurons in mice within two weeks after the stroke, with 3 days showing some integration into the injured area. This is important because it opens up possibilities for new treatments that could help the brain recover better after a stroke.
Who this helps: This helps patients recovering from strokes.
Hess DC, Hill WD, Martin-Studdard A, Carothers J, Brailer J +1 more
Plain English This study looked at what happens to blood cells in the brain after a stroke in mice. Researchers found that after a stroke, cells from the bone marrow can turn into important brain cells that help repair damage, specifically differentiating into cells that make up blood vessels and neurons. This is significant because understanding this process could lead to new treatments that aid recovery after a stroke.
Who this helps: This helps patients recovering from strokes.
ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway.
1999
Genes & development
Kopp E, Medzhitov R, Carothers J, Xiao C, Douglas I +2 more
Plain English Researchers studied a protein called ECSIT, which plays a key role in how our body's immune system responds to infections. They found that ECSIT helps link two important proteins in this response, accelerating the activation of another protein called MEKK-1, which is needed for the immune signal that triggers inflammation. This discovery is important because it helps us understand how our immune system works and could lead to new ways to treat immune-related conditions.
Who this helps: This helps patients with immune system disorders and their doctors.
Carla M Canuso Colette Kosik-Gonzalez Cynthia A Bossie David C Hess William D Hill John Messina Per G Djupesland Ramy A Mahmoud Michael J Archibeck Tamara Cummins
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.